Clearmind Medicine and Yissum expand collaboration with international patent application for generation 3.0 psychedelic compounds to treat mental disorders
- Clearmind Medicine Inc. and Yissum Research Development Company have submitted a patent application under the international Patent Cooperation Treaty (PCT).
- The patent covers generation 3.0 psychedelic compounds, their preparation methods, and uses in treating mental disorders.
- The PCT submission allows the company to seek patent protection in major jurisdictions like the US, Europe, China, and India.
- This collaboration aims to secure intellectual property rights and advance the development of novel psychedelic treatments for mental disorders.
Read more
